CONMED Corp (CNMD) stock
CNMDNYSEElectromedical & Electrotherapeutic ApparatusFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 28, 2026Score 14/3027% below fair value
$49.35−1.24 (-2.45%)
Close on Nov 16, 2026Market cap $1.47BP/E 20.4Yield 1.22%
Conmed EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
Conmed's EPS for the twelve months ending Sep 30, 2026 was $2.42, up 18.0% year over year. For fiscal 2025 it was $1.51, down 64.5% from the year before. Over ten years it grew 3.3% a year on average. The highest annual figure on record is $4.25 in fiscal 2024.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.51 | -64.5% |
| FY2024 | Dec 31, 2024 | $4.25 | +108.3% |
| FY2023 | Dec 31, 2023 | $2.04 | – |
| FY2022 | Dec 31, 2022 | -$2.68 | -238.1% |
| FY2021 | Dec 31, 2021 | $1.94 | +506.3% |
| FY2020 | Dec 31, 2020 | $0.32 | -67.0% |
| FY2019 | Dec 31, 2019 | $0.97 | -31.2% |
| FY2018 | Dec 31, 2018 | $1.41 | -28.4% |
| FY2017 | Dec 31, 2017 | $1.97 | +278.8% |
| FY2016 | Dec 31, 2016 | $0.52 | -52.3% |
| FY2015 | Dec 31, 2015 | $1.09 | -6.0% |
| FY2014 | Dec 31, 2014 | $1.16 | -9.4% |
| FY2013 | Dec 31, 2013 | $1.28 | -9.2% |
| FY2012 | Dec 31, 2012 | $1.41 | +4600.0% |
| FY2011 | Dec 31, 2011 | $0.03 | -97.1% |
| FY2010 | Dec 31, 2010 | $1.05 | +150.0% |
| FY2009 | Dec 31, 2009 | $0.42 | – |
Quarterly eps
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $0.66 | +633.3% |
| Q2 FY2026 | Jun 30, 2026 | $0.77 | +11.6% |
| Q1 FY2026 | Mar 31, 2026 | $0.45 | +136.8% |
| Q4 FY2025 | Dec 31, 2025 | $0.54 | -50.0% |
| Q3 FY2025 | Sep 30, 2025 | $0.09 | -94.3% |
| Q2 FY2025 | Jun 30, 2025 | $0.69 | -28.1% |
| Q1 FY2025 | Mar 31, 2025 | $0.19 | -69.8% |
| Q4 FY2024 | Dec 31, 2024 | $1.08 | +2.9% |
| Q3 FY2024 | Sep 30, 2024 | $1.57 | +214.0% |
| Q2 FY2024 | Jun 30, 2024 | $0.96 | +123.3% |
| Q1 FY2024 | Mar 31, 2024 | $0.63 | +950.0% |
| Q4 FY2023 | Dec 31, 2023 | $1.05 | +20.7% |
| Q3 FY2023 | Sep 30, 2023 | $0.50 | -66.2% |
| Q2 FY2023 | Jun 30, 2023 | $0.43 | – |
| Q1 FY2023 | Mar 31, 2023 | $0.06 | -87.2% |
| Q4 FY2022 | Dec 31, 2022 | $0.87 | +16.0% |
| Q3 FY2022 | Sep 30, 2022 | $1.48 | +214.9% |
| Q2 FY2022 | Jun 30, 2022 | -$5.65 | -1478.0% |
| Q1 FY2022 | Mar 31, 2022 | $0.47 | +51.6% |
| Q4 FY2021 | Dec 31, 2021 | $0.75 | -7.4% |
| Q3 FY2021 | Sep 30, 2021 | $0.47 | +104.3% |
| Q2 FY2021 | Jun 30, 2021 | $0.41 | – |
| Q1 FY2021 | Mar 31, 2021 | $0.31 | +55.0% |
| Q4 FY2020 | Dec 31, 2020 | $0.81 | +65.3% |
| Q3 FY2020 | Sep 30, 2020 | $0.23 | 0.0% |
| Q2 FY2020 | Jun 30, 2020 | -$0.96 | -605.3% |
| Q1 FY2020 | Mar 31, 2020 | $0.20 | +400.0% |
| Q4 FY2019 | Dec 31, 2019 | $0.49 | -9.3% |
| Q3 FY2019 | Sep 30, 2019 | $0.23 | +15.0% |
| Q2 FY2019 | Jun 30, 2019 | $0.19 | -36.7% |
| Q1 FY2019 | Mar 31, 2019 | $0.04 | -89.2% |
| Q4 FY2018 | Dec 31, 2018 | $0.54 | -67.3% |
| Q3 FY2018 | Sep 30, 2018 | $0.20 | -23.1% |
| Q2 FY2018 | Jun 30, 2018 | $0.30 | +36.4% |
| Q1 FY2018 | Mar 31, 2018 | $0.37 | – |
| Q4 FY2017 | Dec 31, 2017 | $1.65 | +587.5% |
| Q3 FY2017 | Sep 30, 2017 | $0.26 | – |
| Q2 FY2017 | Jun 30, 2017 | $0.22 | – |
| Q1 FY2017 | Mar 31, 2017 | -$0.16 | – |
| Q4 FY2016 | Dec 31, 2016 | $0.24 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?